Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection

Andreea Adelina Artenie, Geng Zang, Mark Daniel, Emmanuel Fortier, Didier Jutras-Aswad, Svetlana Puzhko, Julie Bruneau

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background It is unclear whether treatment and care for hepatitis C virus (HCV) infection can help people who inject drugs (PWID) modify their injection drug use behaviours. This study examined changes in injection drug use among PWID with acute HCV systematically referred for HCV clinical assessment and treatment and offered targeted health care services, over the course of one year. Methods The study sample included PWID with documented acute HCV infection recruited and followed-up semi-annually at least twice in IMPACT (2007–2015), a longitudinal community-based prospective study in Montréal, Canada. Following enrolment, participants with contra-indications to treatment due to severe co-morbidity were offered targeted health care services. Pegylated interferon-alpha (12–24 weeks) was offered to all other participants who did not spontaneously resolve their infection. At each study visit, data were collected on socio-demographic factors and drug use patterns. Logistic regression was used to assess changes in injection drug use at one-year follow-up. Results Of the 87 eligible participants (mean age: 35.6; 78.2% male), 21.8% received treatment [(RT), Sustained virological response: 84.2%], 25.3% spontaneously resolved their infection (SR), 14.9% had contra-indication(s) (CI) and 37.9% chose not to engage in HCV care post-diagnosis (NE). In multivariate analyses adjusting for age, gender and injection drug use at baseline, the RT [Adjusted odds ratio (AOR): 0.18; 95% Confidence interval (CI): 0.04–0.76], SR (AOR: 0.34; 95% CI: 0.08–1.40), and CI (AOR: 0.24; 95% CI: 0.05–1.22) groups were less likely to report injection drug use at follow-up relative to the NE group. Conclusion PWID who received treatment, spontaneously resolved their infection or presented with treatment contra-indication(s) reported reduced injection drug use at one-year follow-up relative to those who did not engage in therapy. Findings suggest that the benefits of HCV assessment and treatment may extent to helping PWID modify their injection drug use patterns.

Original languageEnglish
Pages (from-to)239-243
Number of pages5
JournalInternational Journal of Drug Policy
Volume47
DOIs
Publication statusPublished - Sep 2017
Externally publishedYes

Fingerprint

Virus Diseases
Hepacivirus
Injections
Pharmaceutical Preparations
Confidence Intervals
Therapeutics
Odds Ratio
Health Services
Infection
Delivery of Health Care
Interferon-alpha
Canada
Multivariate Analysis
Logistic Models
Demography
Prospective Studies

Cite this

Artenie, Andreea Adelina ; Zang, Geng ; Daniel, Mark ; Fortier, Emmanuel ; Jutras-Aswad, Didier ; Puzhko, Svetlana ; Bruneau, Julie. / Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. In: International Journal of Drug Policy. 2017 ; Vol. 47. pp. 239-243.
@article{ea8560fdfa9848b9ac6e37e8e9b495c9,
title = "Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection",
abstract = "Background It is unclear whether treatment and care for hepatitis C virus (HCV) infection can help people who inject drugs (PWID) modify their injection drug use behaviours. This study examined changes in injection drug use among PWID with acute HCV systematically referred for HCV clinical assessment and treatment and offered targeted health care services, over the course of one year. Methods The study sample included PWID with documented acute HCV infection recruited and followed-up semi-annually at least twice in IMPACT (2007–2015), a longitudinal community-based prospective study in Montr{\'e}al, Canada. Following enrolment, participants with contra-indications to treatment due to severe co-morbidity were offered targeted health care services. Pegylated interferon-alpha (12–24 weeks) was offered to all other participants who did not spontaneously resolve their infection. At each study visit, data were collected on socio-demographic factors and drug use patterns. Logistic regression was used to assess changes in injection drug use at one-year follow-up. Results Of the 87 eligible participants (mean age: 35.6; 78.2{\%} male), 21.8{\%} received treatment [(RT), Sustained virological response: 84.2{\%}], 25.3{\%} spontaneously resolved their infection (SR), 14.9{\%} had contra-indication(s) (CI) and 37.9{\%} chose not to engage in HCV care post-diagnosis (NE). In multivariate analyses adjusting for age, gender and injection drug use at baseline, the RT [Adjusted odds ratio (AOR): 0.18; 95{\%} Confidence interval (CI): 0.04–0.76], SR (AOR: 0.34; 95{\%} CI: 0.08–1.40), and CI (AOR: 0.24; 95{\%} CI: 0.05–1.22) groups were less likely to report injection drug use at follow-up relative to the NE group. Conclusion PWID who received treatment, spontaneously resolved their infection or presented with treatment contra-indication(s) reported reduced injection drug use at one-year follow-up relative to those who did not engage in therapy. Findings suggest that the benefits of HCV assessment and treatment may extent to helping PWID modify their injection drug use patterns.",
keywords = "Antiviral treatment, Cohort study, HCV, Hepatitis C care, Injection drug use, People who inject drugs",
author = "Artenie, {Andreea Adelina} and Geng Zang and Mark Daniel and Emmanuel Fortier and Didier Jutras-Aswad and Svetlana Puzhko and Julie Bruneau",
year = "2017",
month = "9",
doi = "10.1016/j.drugpo.2017.05.033",
language = "English",
volume = "47",
pages = "239--243",
journal = "International Journal of Drug Policy",
issn = "0955-3959",
publisher = "Elsevier",

}

Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection. / Artenie, Andreea Adelina; Zang, Geng; Daniel, Mark; Fortier, Emmanuel; Jutras-Aswad, Didier; Puzhko, Svetlana; Bruneau, Julie.

In: International Journal of Drug Policy, Vol. 47, 09.2017, p. 239-243.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection

AU - Artenie, Andreea Adelina

AU - Zang, Geng

AU - Daniel, Mark

AU - Fortier, Emmanuel

AU - Jutras-Aswad, Didier

AU - Puzhko, Svetlana

AU - Bruneau, Julie

PY - 2017/9

Y1 - 2017/9

N2 - Background It is unclear whether treatment and care for hepatitis C virus (HCV) infection can help people who inject drugs (PWID) modify their injection drug use behaviours. This study examined changes in injection drug use among PWID with acute HCV systematically referred for HCV clinical assessment and treatment and offered targeted health care services, over the course of one year. Methods The study sample included PWID with documented acute HCV infection recruited and followed-up semi-annually at least twice in IMPACT (2007–2015), a longitudinal community-based prospective study in Montréal, Canada. Following enrolment, participants with contra-indications to treatment due to severe co-morbidity were offered targeted health care services. Pegylated interferon-alpha (12–24 weeks) was offered to all other participants who did not spontaneously resolve their infection. At each study visit, data were collected on socio-demographic factors and drug use patterns. Logistic regression was used to assess changes in injection drug use at one-year follow-up. Results Of the 87 eligible participants (mean age: 35.6; 78.2% male), 21.8% received treatment [(RT), Sustained virological response: 84.2%], 25.3% spontaneously resolved their infection (SR), 14.9% had contra-indication(s) (CI) and 37.9% chose not to engage in HCV care post-diagnosis (NE). In multivariate analyses adjusting for age, gender and injection drug use at baseline, the RT [Adjusted odds ratio (AOR): 0.18; 95% Confidence interval (CI): 0.04–0.76], SR (AOR: 0.34; 95% CI: 0.08–1.40), and CI (AOR: 0.24; 95% CI: 0.05–1.22) groups were less likely to report injection drug use at follow-up relative to the NE group. Conclusion PWID who received treatment, spontaneously resolved their infection or presented with treatment contra-indication(s) reported reduced injection drug use at one-year follow-up relative to those who did not engage in therapy. Findings suggest that the benefits of HCV assessment and treatment may extent to helping PWID modify their injection drug use patterns.

AB - Background It is unclear whether treatment and care for hepatitis C virus (HCV) infection can help people who inject drugs (PWID) modify their injection drug use behaviours. This study examined changes in injection drug use among PWID with acute HCV systematically referred for HCV clinical assessment and treatment and offered targeted health care services, over the course of one year. Methods The study sample included PWID with documented acute HCV infection recruited and followed-up semi-annually at least twice in IMPACT (2007–2015), a longitudinal community-based prospective study in Montréal, Canada. Following enrolment, participants with contra-indications to treatment due to severe co-morbidity were offered targeted health care services. Pegylated interferon-alpha (12–24 weeks) was offered to all other participants who did not spontaneously resolve their infection. At each study visit, data were collected on socio-demographic factors and drug use patterns. Logistic regression was used to assess changes in injection drug use at one-year follow-up. Results Of the 87 eligible participants (mean age: 35.6; 78.2% male), 21.8% received treatment [(RT), Sustained virological response: 84.2%], 25.3% spontaneously resolved their infection (SR), 14.9% had contra-indication(s) (CI) and 37.9% chose not to engage in HCV care post-diagnosis (NE). In multivariate analyses adjusting for age, gender and injection drug use at baseline, the RT [Adjusted odds ratio (AOR): 0.18; 95% Confidence interval (CI): 0.04–0.76], SR (AOR: 0.34; 95% CI: 0.08–1.40), and CI (AOR: 0.24; 95% CI: 0.05–1.22) groups were less likely to report injection drug use at follow-up relative to the NE group. Conclusion PWID who received treatment, spontaneously resolved their infection or presented with treatment contra-indication(s) reported reduced injection drug use at one-year follow-up relative to those who did not engage in therapy. Findings suggest that the benefits of HCV assessment and treatment may extent to helping PWID modify their injection drug use patterns.

KW - Antiviral treatment

KW - Cohort study

KW - HCV

KW - Hepatitis C care

KW - Injection drug use

KW - People who inject drugs

UR - http://www.scopus.com/inward/record.url?scp=85020095979&partnerID=8YFLogxK

UR - http://www.mendeley.com/research/shortterm-injection-drug-changes-following-hepatitis-c-virus-hcv-assessment-treatment-among-persons

U2 - 10.1016/j.drugpo.2017.05.033

DO - 10.1016/j.drugpo.2017.05.033

M3 - Article

VL - 47

SP - 239

EP - 243

JO - International Journal of Drug Policy

JF - International Journal of Drug Policy

SN - 0955-3959

ER -